Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Echocardiographic and Biochemical Studies
2.3. Ethical Considerations
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Patil, A.; Majumdar, S. Echinocandins in antifungal pharmacotherapy. J. Pharm. Pharmacol. 2017, 69, 1635–1660. [Google Scholar] [CrossRef]
- Pappas, P.G.; Kauffman, C.A.; Andes, D.R.; Clancy, C.J.; Marr, K.A.; Ostrosky-Zeichner, L.; Reboli, A.; Schuster, M.; Vazquez, J.; Walsh, T.; et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016, 62, e1–e50. [Google Scholar] [CrossRef]
- Lichtenstern, C.; Wolff, M.; Arens, C.; Klie, F.; Majeed, R.W.; Henrichm, M.; Weiterer, S.; Rohrig, R.; Weigand, M. Cardiac effects of echinocandin preparations—three case reports. J. Clin. Pharm. Ther. 2013, 38, 429–431. [Google Scholar] [CrossRef]
- Fink, M.; Zerlauth, U.; Kaulfersch, C.; Rab, A.; Alberer, D.; Preiss, P.; Sternad-Klobschauer, K.; Habernig, E.; Wandschneider, W.; Grimm, G. A severe case of haemodynamic instability during anidulafungin administration. J. Clin. Pharm. Ther. 2013, 38, 241–242. [Google Scholar] [CrossRef]
- Hindahl, C.B.; Wilson, J.W. Flash pulmonary oedema during anidulafungin administration. J. Clin. Pharm. Ther. 2012, 37, 491–493. [Google Scholar] [CrossRef] [PubMed]
- Arens, C.; Uhle, F.; Wolff, M.; Röhrig, R.; Koch, C.; Schulte, A.; Weiterer, S.; Henrich, M.; Weigand, M.A.; Schlüter, K.D.; et al. Effects of echinocandin preparations on adult rat ventricular cardiomyocytes. Preliminary results of an in vitro study. Anaesthesist 2014, 63, 129–134. [Google Scholar] [CrossRef] [PubMed]
- Koch, C.; Uhle, F.; Wolff, M.; Arens, C.; Schulte, A.; Li, L.; Niemann, B.; Henrich, M.; Rohrbach, S.; Weigand, M.; et al. Cardiac effects of echinocandins after central venous administration in adult rats. Antimicrob. Agents Chemother. 2015, 59, 1612–1619. [Google Scholar] [CrossRef] [PubMed]
- Koch, C.; Wolff, M.; Henrich, M.; Weigand, M.A.; Lichtenstern, C.; Uhle, F. Cardiac effects of echinocandins in endotoxemic rats. Antimicrob. Agents Chemother. 2015, 60, 301–306. [Google Scholar] [CrossRef] [PubMed]
- Koch, C.; Jersch, J.; Schneck, E.; Edinger, F.; Maxeiner, H.; Uhle, F.; Weigand, M.A.; Markmann, M.; Sander, M.; Henrich, M. Caspofungin modulates ryanodine receptor-mediated calcium release in human cardiac myocytes. Antimicrob. Agents Chemother. 2018, 62, e01114-8. [Google Scholar] [CrossRef] [PubMed]
- Lahmer, T.; Schnappauf, C.; Messer, M.; Rasch, S.; Fekecs, L.; Beitz, A.; Eser, S.; Schmid, R.; Huber, W. Influence of echinocandin administration on hemodynamic parameters in medical intensive care unit patients: A single center prospective study. Infect. 2015, 43, 723–727. [Google Scholar] [CrossRef] [PubMed]
- Stover, K.R.; Cleary, J.D. Cardiac response to centrally administered echinocandin antifungals. J. Pharm. Pharmacol. 2015, 67, 1279–1283. [Google Scholar] [CrossRef] [PubMed]
- Cleary, J.D.; Stover, K.R. Antifungal-associated drug-induced cardiac disease. Clin. Infect. Dis. 2015, 61 (Suppl. 6), S662–S668. [Google Scholar] [CrossRef] [PubMed]
- Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). J. Am. Coll. Cardiol. 2018, 72, 2231–2264. [Google Scholar] [CrossRef] [PubMed]
- Collet, J.P.; Thiele, H.; Barbato, E.; Barthélémy, O.; Bauersachs, J.; Bhatt, D.L.; Dendale, P.; Dorobantu, M.; Edvardsen, T.; Folliguet, T.; et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021, 42, 1289–1367. [Google Scholar] [CrossRef] [PubMed]
- Zamorano, J.L.; Lancellotti, P.; Rodriguez Munoz, D.; Aboyans, V.; Asteggiano, R.; Galderisi, M.; Habib, G.; Lenihan, D.J.; Lip, G.Y.; Lyon, A.R.; et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J. 2016, 37, 2768–2801. [Google Scholar] [CrossRef] [PubMed]
- Berliner, D.; Beutel, G.; Bauersachs, J. Echocardiography and biomarkers for the diagnosis of cardiotoxicity. Herz. 2020, 45, 637–644. [Google Scholar] [CrossRef] [PubMed]
- McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726. [Google Scholar] [CrossRef] [PubMed]
- Stover, K.R.; King, S.T.; Cleary, J.D. Cardiac toxicity of the echinocandins: Chance or cause and effect association? J. Clin. Pharm. Ther. 2014, 39, 1–3. [Google Scholar] [CrossRef] [PubMed]
- Kofla, G.; Ruhnke, M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: Review of the literature. Eur. J. Med. Res. 2011, 16, 159–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Parameter | Before | After | p-Value |
---|---|---|---|
Eyeball LVEF | 55 ± 0 | 54.6 ± 1.2 | 0.3 |
Simpson LVEF | 55.1 ± 8.6 | 54.4 ± 6.6 | 0.79 |
GLS | −16.2 ± 3.5 | −16.5 ± 2.4 | 0.66 |
Tei index | 0.29 ± 0.07 | 0.27 ± 0.05 | 0.47 |
E/E′ | 9.13 ± 2.2 | 9.15 ± 2.6 | 0.9 |
LAVI | 26.3 ± 9 | 25.3 ± 6 | 0.62 |
N | Mean of the Difference | SD of the Difference | p-Value of the Difference | 95% CI of the Difference | |
---|---|---|---|---|---|
Simpson LVEF 1&2 | 15 | −0.73 | 10.68 | 0.7 | −6.6–5.1 |
GLS 1&2 | 15 | 0.38 | 3.35 | 0.6 | −1.4–2.2 |
Tei index1&2 | 15 | 0.01 | 0.08 | 0.4 | −0.02–0.06 |
LAVI 1&2 | 15 | 1.01 | 7.74 | 0.6 | −3.2–5.3 |
hs-cTnI 1&2 | 15 | −0.11 | 0.13 | 0.006 | −0.1–0.03 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sattarzadeh Badkoubeh, R.; Farajpour, M.; Salehi, M.; Sherafati, A.; Zamani, Z.; Rezahosseini, O.; Mansouri, P.; Sardari, A. Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia. Toxics 2022, 10, 521. https://doi.org/10.3390/toxics10090521
Sattarzadeh Badkoubeh R, Farajpour M, Salehi M, Sherafati A, Zamani Z, Rezahosseini O, Mansouri P, Sardari A. Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia. Toxics. 2022; 10(9):521. https://doi.org/10.3390/toxics10090521
Chicago/Turabian StyleSattarzadeh Badkoubeh, Roya, Mostafa Farajpour, Mohammadreza Salehi, Alborz Sherafati, Zahra Zamani, Omid Rezahosseini, Pejman Mansouri, and Akram Sardari. 2022. "Caspofungin-Induced Cardiotoxicity in Patients Treating for Candidemia" Toxics 10, no. 9: 521. https://doi.org/10.3390/toxics10090521